切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2017, Vol. 10 ›› Issue (02) : 187 -191. doi: 10.3877/cma.j.issn.1674-6902.2017.02.015

所属专题： 专题评论； 文献；

论著

血清可溶性人基质裂解素2和降钙素原水平的变化在AECOPD患者中的病情评估
朱默然1, 许德凤2,†(), 赵云峰3, 刘锦铭4, 赵蕾2   
  1. 2. 200135　上海，上海市浦东新区公利医院呼吸内科
    3. 200125　上海，上海市浦东新区浦南医院呼吸内科
    4. 200433　上海，上海市肺科医院肺循环科
  • 收稿日期:2016-11-10 出版日期:2017-04-20
  • 通信作者: 许德凤
  • 基金资助:
    上海市浦东新区卫生系统重点专科建设项目资助(PWZZ2013－07)

Index changes of serumal soluble human stromelysin-2 and procalcitonin assess the patients of AECOPD

Moran Zhu1, Defeng Xu2,†(), Yunfeng Zhao3, Jinming Liu4, Lei Zhao2   

  1. 1. Ningxia Medical University, Yinchuan 750003, China
    2. Respiratory Medicine, Gongli Hospital, the Second Military Medical University, Shanghai 200135
    3. Respiratory Medicine, Shanghai Punan Hospital, Shanghai 200125, China
    4. Department of pulmonary circulation, Pulmonary Hospital, Shanghai 200433, China
  • Received:2016-11-10 Published:2017-04-20
  • Corresponding author: Defeng Xu
  • About author:
    Corresponding author: Xu Defeng, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

朱默然, 许德凤, 赵云峰, 刘锦铭, 赵蕾. 血清可溶性人基质裂解素2和降钙素原水平的变化在AECOPD患者中的病情评估[J]. 中华肺部疾病杂志(电子版), 2017, 10(02): 187-191.

Moran Zhu, Defeng Xu, Yunfeng Zhao, Jinming Liu, Lei Zhao. Index changes of serumal soluble human stromelysin-2 and procalcitonin assess the patients of AECOPD[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(02): 187-191.

目的

探讨血清可溶性人基质裂解素2(sST2)与慢性阻塞性肺疾病急性加重期(AECOPD)患者病情严重程度的关系及临床意义。

方法

检测120例(Ⅰ级30例、Ⅱ级30例、Ⅲ级30例和Ⅳ级30例)AECOPD患者治疗前后的血清sST2、降钙素原(PCT)、C反应蛋白(CRP)水平，并分析血清sST2、PCT、CRP水平与CAT评分、6 min步行距离(6 minutes walk distance, 6MWD)之间的相关性。另选择30例体检正常人员作为对照组。

结果

①AECOPD组治疗前血清sST2、PCT、CRP水平显著高于治疗后和对照组(P值均<0.05)，且在一定程度上随着病情严重程度的增加而增加；②COPD严重程度分级与血清sST2、CRP、PCT水平存在相关性(r＝0.588，r＝0.447，r＝0.305，P值均小于0.01)，Ⅰ级、Ⅱ级COPD患者血清sST2水平明显低于Ⅲ级、Ⅳ级患者(t＝9.600，P<0.01)；③血清sST2水平与患者CAT量表呈正相关(r＝0.363，P<0.01)，随着血清sST2水平的升高，CAT量表数值也升高；与6MWD呈负相关(r＝－0.434，P<0.01)，随着血清sST2水平的升高，6MWD距离下降。

结论

Ⅲ级、Ⅳ级AECOPD患者血清sST2水平高于Ⅰ级、Ⅱ级AECOPD患者，随病情好转，血清sST2水平降低显著。血清sST2水平可以在一定程度上反映AECOPD患者病情严重程度，对AECOPD患者病情评估具有临床价值。

关键词: 急性加重，肺疾病，慢性阻塞性, 可溶性人基质裂解素2, 降钙素原, C反应蛋白, CAT评分量表, 6 min步行试验
Objective

To analyse the severity of disease and the evaluation of serum quality of life value of serumal soluble human stromelysin-2 and procalcitonin in the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

Methods

The serumal soluble human stromelysin-2, procalcitonin, C reactive protein were detected in 120 hospitalized AECOPD patients before and after the treatment, and to study the correlation above indexes with severity of COPD, COPD assessment test(CAT) and 6 minutes walk distance (6MWD).

Results

Compared with after the treatment patients and healthy control group, serumal levels of the soluble human stromelysin-2, procalcitonin, C-reactive protein were significantly elevated in the patient with AECOPD before the treatment(P<0.05). To some extent, the levels of these indicators were increasing with the increase in the severity of the disease. The severity classification of COPD were positively correlated with serum sST2, CRP and PCT levels (r=0.588, r=0.132, r=0.305, P<0.01), serum sST2 level of the combined Class Ⅰ and Ⅱ COPD patients was significantly lower than the combined Class Ⅲ and Ⅳ COPD patients (t=9.600, P<0.01). The serumal sST2 was positively correlated with CAT (r=0.363, P<0.01), and was negatively correlated with 6MWD (r=-0.434, P<0.01).

Conclusions

The serumal sST2 levels in Ⅲ, Ⅳ level AECOPD patients were higher than Ⅰ, Ⅱ stage AECOPD patients, and with the condition improved, serumal sST2 decreased significantly. Serumal sST2 can reflect the severity of AECOPD patients in some extent, and has certain clinical value to evaluate the condition of AECOPD patients.

Key words: Acute exacerbation of chronic obstructive pulmonary disease, Soluble human stromelysin-2, Procalcitonin, C-reactive protein, COPD assessment test, 6 minutes walk test
表1 不同级别AECOPD患者治疗前后血清sST2、PCT、CRP含量差异性
分　级 治疗前/后 CRP(mg/L) PCT(ng/ml) sST2(ng/L)
Ⅰ级(n＝30) 治疗前 22.33±16.05 0.24±0.13 107.96±46.71
? 治疗后 4.87±3.06 0.06±0.05 72.24±12.25
? t值 2.426 3.014 4.878
? 前后比较P值 0.022 0.005 0.000
Ⅱ级(n＝30) 治疗前 30.02±20.17 0.32±0.19 178.57±66.62
? 治疗后 6.04±4.43 0.03±0.02 90.66±29.44
? t值 3.281 4.112 10.216
? 前后比较P值 0.003 0.000 0.000
Ⅲ级(n＝30) 治疗前 25.14±17.17 1.32±0.29 238.93±101.44
? 治疗后 7.16±3.58 0.33±0.12 89.03±18.13
? t值 3.663 2.520 8.835
? 前后比较P值 0.001 0.017 0.000
Ⅳ级(n＝30) 治疗前 63.43±28.82 3.60±1.20 394.67±88.60
? 治疗后 8.84±4.51 0.04±0.01 114.41±29.95
? t值 5.426 5.024 17.438
? 前后比较P值 0.000 0.000 0.000
对照组(n＝30) ? 0.99±0.90 0.06±0.05 66.91±8.20
? t值 7.167 3.072 13.476
? 与AECOPD患者治疗后P值 0.000 0.003 0.000
图1 AECOPD患者治疗后血清sST2水平与CAT量表之间的散点图
图2 120例AECOPD患者治疗后血清sST2水平与6MWD的散点图
1
任成山，钱桂生. 慢性阻塞性肺疾病发病机制研究现状与展望[J/CD]. 中华肺部疾病杂志(电子版), 2009, 2(2): 104-115.
2
Sandhu SK, Chu J, Yurkovich M, et al. Variations in the management of acute exacerbations of chronic obstructive pulmonary disease[J]. Can Respir J, 2013, 20(3): 175-179.
3
包鹤龄，方利文，王临虹. 1990-2014年中国40岁及以上人群慢性阻塞性肺疾病患病率Meta分析[J]. 中华流行病学杂志，2016, 37(1): 119-124.
4
Benoit JL, Hicks CW, Engineer RS, et al. ST2 in emergency department patients with noncardiac dyspnea[J]. Acad Emerg Med, 2013, 20(11): 1207-1210.
5
Hoogerwerf JJ, Tanck MW, van Zoelen MA, et al. Soluble ST2 plasma concentrations predict mortality in severe sepsis[J]. Intensive Care Med, 2010, 36(4): 630-637.
6
Bajwa EK, Volk JA, Christiani DC, et al. Prognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome[J]. Crit Care Med, 2013, 41(11): 2521-2531.
7
Watanabe M, Takizawa H, Tamura M, et al. Soluble ST2 as a prognostic marker in community-acquired pneumonia[J]. J Infect, 2015, 70(5): 474-482.
8
Calò Carducci FI, Aufiero LR, Folgori L, et al. Serum soluble ST2 as diagnostic marker of systemic inflammatory reactive syndrome of bacterial etiology in Children[J]. Pediatr Infect Dis J, 2014, 33(2): 199-203.
9
Sahlander K, Larsson K, Palmberg L. Daily exposure to dust alters innate immunity[J]. PLoS ONE, 2012, 7(2): e31646.
10
Lee M, Snyder A. The role of procalcitonin in community-acquired pneumonia: a literature review[J]. Adv Emerg Nurs J, 2012, 34(3): 259-271.
11
Schuetz P, Litke A, Albrich WC, et al. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia[J]. Curr Opin Infect Dis, 2013, 26(2): 159-167.
12
Kozdag G, Ertas G, Kilic T, et al. Elevated level of high sensitivity C-reactive protein is important in determining prognosis in chronic heart failure[J]. Med Sci Monit, 2010, 16(3): 156-161.
13
Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test[J]. Eur Respir J, 2009, 34(3): 648-654.
14
Hernandes NA, Wouters EF, Meijer K, et al. Reproducibility of 6-minute walking test in patients with COPD[J]. Eur Respir J, 2011, 38(2): 261-267.
15
Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2015)[EB/OL]. [2015-01]．
16
Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis，management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary[J]. Am J Respir Crit Care Med, 2013, 187(4): 347-365.
17
Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33：the new kid in the IL-1 family[J]. Nat Rev Immunol, 2010, 10(2): 103-110.
18
Jing Lin, Zhang Lili, Zhao Guiqiu, et al. A Novel interleukin 33/ST2 signaling regulates inflammatory response in Human Corneal Epithelium[J]. PLoS ONE, 2013, 8(4): e60963.
19
Martinez-Rumayor A, Camargo CA, Green SM, et al. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease[J]. Am J Clin Pathol, 2008, 130(4): 578-584.
20
Hacker S, Lambers C, Pollreisz A, et al. Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune responsein COPD[J]. Clin Lab Anal, 2009, 23(6): 372-379.
21
Wu H, Yang S, Wu X, et al. Interleukin-33/ST2 signaling promotes production of interleukin-6 andinterleukin-8 in systemic inflammationin cigarette smoke-induced chronic obstructive pulmonary disease mice[J]. Biochem Biophys Res Commun, 2014, 450(1): 110-116.
22
文健，周泽云. 探讨血清ST2在重症慢性阻塞性肺疾病中的表达及作用[J]. 中国医学前沿杂志，2015, 7(10): 80-83.
[1] 涂家金, 廖武强, 刘金晶, 涂志鹏, 毛远桂. 严重烧伤患者鲍曼不动杆菌血流感染的危险因素及预后分析[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 491-497.
[2] 廖锵云, 王震, 林洁玉, 廖夏, 邓锦华, 李杰峰, 邓建维, 李明, 荣新洲. 虎门地区创伤弧菌感染的临床观察[J]. 中华损伤与修复杂志(电子版), 2023, 18(05): 394-398.
[3] 王龙彪, 刘洪, 董天雄. 中心体扩增细胞占比和C反应蛋白-白蛋白比值对胃癌根治术治疗预后的预测价值[J]. 中华普通外科学文献(电子版), 2023, 17(05): 352-356.
[4] 冯树森, 张东成, 郭奇, 张皓露, 陈阔. 两种手术方法对急性阑尾炎患者的临床疗效及对炎性因子的影响比较[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 447-450.
[5] 伍学成, 李远伟, 袁武雄, 王建松, 石泳中, 卢强, 李卓, 陈佳, 刘哲, 滕伊漓, 高智勇. 炎症介质谱联合降钙素原在尿源性脓毒血症中的诊断价值[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 476-480.
[6] 刘立, 陈诚, 李新科, 刘凯, 屠昌明. 血清IL-6、hs-CRP、MMP-9联合检测在腹股沟疝无张力修补术预后评价中的价值分析[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(04): 405-409.
[7] 李海明, 刘鸿飞, 李俊. 血清脂蛋白酶水平与COPD患者骨骼肌质量减少的关系[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 500-503.
[8] 芦丹, 杨硕, 刘旭. VEGF、HMGB1、hs-CRP/Alb在AECOPD伴呼吸衰竭中的变化及预后分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 532-534.
[9] 吴庆华, 冒勇, 闫效坤. AECOPD并发AKI的危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 529-531.
[10] 安钱, 徐彬, 陈志祥, 徐晶晶, 黄丹丹. PCT、CRP及SAA对呼吸机相关性肺炎病情严重程度和预后分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 544-546.
[11] 廖玥, 王可, 秦江月, 吴艳秋, 陈俊, 汪涛, 文富强, 王浩. 丹龙口服液治疗轻中度慢性阻塞性肺疾病急性加重期的多中心及前瞻性研究[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 306-311.
[12] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[13] 卓少宏, 林秀玲, 周翠梅, 熊卫莲, 马兴灶. CD64指数、SAA/CRP、PCT联合检测在小儿消化道感染性疾病鉴别诊断中的应用[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 505-509.
[14] 孙旻. 血液淀粉酶、C反应蛋白、降钙素原及乳酸脱氢酶在急性胰腺炎患者病情评价及预后预测中的价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 331-336.
[15] 王庆, 夏婷婷. 未成熟粒细胞计数、C反应蛋白、中性粒细胞/淋巴细胞、降钙素原结合MCTSI评分在急性胆源性胰腺炎中的诊断价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 224-228.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号